10/27/2014

ImmunoSite Earns ISO 9001:2008 and ISO 13485:2003 Dual Certification

Miramar, Fla. – October 7, 2014 – ImmunoSite Technologies, LLC, a leading global provider of contract R&D services, announces their dual ISO certification from NQA as another step in their commitment to quality and customer service. ImmunoSite Technologies Automation Services are concentrated on fulfilling the special needs of life science industries.  Turnkey custom  integrated solutions […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


05/22/2014

Biomarkers Enhance Astra Zeneca's Clinical Trial Successes

Tags: , ,

Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug development process.

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


02/10/2014

ImmunoSite Receives 2013 Innovative Business Award

ImmunoSite Technologies, LLC receives the 2013 Innovative Business award

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


02/02/2014

ImmunoSite Receives National MBE Certification

02/01/2014. ImmunoSite Technologies was certified as a National MBE, Minority Business Enterprise, by the Southern Florida Minority Supplier Development Council as defined by the U.S. National Minority Supplier Development Council.  The NMSDC was chartered in 1972 and is one of the country’s leading corporate membership organizations to advance business opportunities for certified business enterprises of all […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


03/03/2013

ImmunoSite Technologies Expands into New Spacious Facility in Miramar

Tags: , , , ,

Press Release, February 28, 2013 ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current employees, making a capital investment […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


01/19/2013

2013 SLAS 2nd Annual Conference & Exhibition

Tags: , , ,

Executives, Engineers, and Scientists from ImmunoSite Technologies attended the Annual 2013 SLAS meeting in Orlando, Florida and brought back some of the latest technologies to integrate into new automated solutions for biological assay automation that will enhance their client’s productivity even more! Call IST to discuss your automation needs at (888) 770-4478 Share this:

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


10/18/2012

ImmunoSite Technologies Aides in Curriculum Development for Employ Florida Banner Center

Tags: , ,

Cell Culture Course helps Floridians enter, remain and advance in the workforce Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped to develop a Cell Culture Workshop that is offered  at the Employ Florida Banner Center for Life Sciences, based at Palm Beach […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading


04/03/2011

ImmunoSite Technologies Provides Particle Testing Services to Beckman Coulter Customers

Tags: , , , , , , , ,

IST employs a wide range of particle testing technologies

Leading provider of particle testing services now receives referrals of customers seeking particle characterization services from Beckman Coulter, Inc. Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a […]

Share this:
  • Print
  • Digg
  • Facebook
  • email
  • LinkedIn
  • Twitter
Continue Reading